Esther Rajavelu named Spero CEO effective May 2; former CEO Sath Shukla departs

Spero Therapeutics, Inc.

Esther Rajavelu appointed President and CEO effective May 2, 2025; nominated for board election at annual meeting.
Rajavelu continues as CFO and Treasurer; base salary $620K, target bonus 50%, 185,000 RSUs vesting over 4 years.
Former CEO Sath Shukla mutually separates; receives salary continuation of $615,825, cash bonus $307,913, and retention bonus $452,813.
Company expects update on PIVOT-PO Phase 3 trial for tebipenem HBr this quarter.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Esther Rajavelu

President and Chief Executive Officer

SPRO · Spero Therapeutics, Inc.

Effective: 2025-05-02
Filed: April 28, 2025, 7:59 PM ET

On April 28, 2025, Spero Therapeutics, Inc. (the “Company”) announced that effective as of May 2, 2025 (the “Effective Date”), Esther Rajavelu will serve as the Company’s President and Chief Executive Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Esther Rajavelu was appointed as President and Chief Executive Officer at Spero Therapeutics, Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

On April 28, 2025, Spero Therapeutics, Inc. (the “Company”) announced that effective as of May 2, 2025 (the “Effective Date”), Esther Rajavelu will serve as the Company’s President and Chief Executive Officer.

View on SEC.gov

Spero Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-100433

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.